vimarsana.com

Page 5 - Source Ucb Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesBruxelles capitaleMjamesf howardJim baxterIris loew friedrichAntje witteSeanm healeyHoward jf jrNatalie jonesRaquel pardoBrand communicationsSpanish myasthenia associationRare disease communicationsEuropean unionMyasthenia gravis foundation of americaCorporate communications

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

/PRNewswire/ UCB, a global biopharmaceutical company, today announced positive top-line results from the Phase 3 BE COMPLETE study, which evaluated the.

United statesBruxelles capitaleNicole hergaJosephf merolaEmmanuel caeymaexEimear obrienJ clin pharmacolAntje witteImmunology solutionsBrand communicationsDrug administrationHealth assessment questionnaireHarvard medical schoolAmerican college of rheumatologyHealth surveyEuropean union

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesBruxelles capitaleNicole hergaJosephf merolaEmmanuel caeymaexEimear obrienJ clin pharmacolAntje witteImmunology solutionsBrand communicationsDrug administrationHealth assessment questionnaireHarvard medical schoolAmerican college of rheumatologyHealth surveyEuropean union

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

/PRNewswire/ UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study.

United statesUnited kingdomBruxelles capitaleNicole hergaEmmanuel caeymaexMusculoskelet disordEimear obrienAntje witteJ clin pharmacolImmunology solutionsBrand communicationsDrug administrationDivision of arthritisAssessment of spondyloarthritis international societyEuropean unionCorporate communications

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

/PRNewswire/ UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study.

United statesUnited kingdomBruxelles capitaleNicole hergaEmmanuel caeymaexMusculoskelet disordEimear obrienAntje witteJ clin pharmacolImmunology solutionsBrand communicationsDrug administrationDivision of arthritisAssessment of spondyloarthritis international societyEuropean unionCorporate communications

vimarsana © 2020. All Rights Reserved.